The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2022 | ASCO 2022: Highlights in lung cancer
Joshua K. Sabari, MD, NYU Langone Health, New York, NY, provides his highlights in the field of lung cancer presented at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting, including updates in adagrasib, a KRAS G12C inhibitor for non–small cell lung cancer (NSCLC), especially in patients with brain metastases. Additional highlights include findings from the phase I CHRYSALIS trial (NCT02609776) assessing amivantamab, an EGFR-MET bispecific antibody, novel strategies to MET exon 14 skipping mutations, as well as antibody-drug conjugates (ADCs). This interview took place at the ASCO 2022 Annual Meeting in Chicago, IL.
